Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk PV or ET (MPD-RC 111)
NCT01259817Phase 2Completed
- Start
- Sep 2011
- Primary completion
- Dec 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a in polycythemia vera (PV) and essential thrombocythemia (ET). Primary endpoint: Complete Response or Partial Response at 4 years. Started Sep 2011; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT01259817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259817.